Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

[1] Shih K(2014)Clinical impact of checkpoint inhibitors as novel cancer therapies Drugs 74 1993-2013

[2] Arkenau HT(2015)PD-1/PD-L1 inhibitors Curr Opin Pharmacol 23 32-38

[3] Infante JR(2015)Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer Sci Rep 5 13110-988

[4] Sunshine J(2016)Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer J Thorac Oncol 11 976-54

[5] Taube JM(2015)Differential activity of Nivolumab, Pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers PLoS One 10 e0130142-331

[6] He J(2016)Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer JAMA Oncology 2 46-975

[7] Hu Y(2016)Programmed death ligand 1 immunohistochemistry: friend or foe? Arch Pathol Lab Med 140 326-1421

[8] Hu M(2016)PD-L1 expression in lung cancer J Thorac Oncol 11 964-222

[9] Li B(2017)PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability Mod Pathol 30 1411-567

[10] Shukuya T(2017)PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project J Thorac Oncol 12 208-361

[1] Shih K(2014)Clinical impact of checkpoint inhibitors as novel cancer therapies Drugs 74 1993-2013

[2] Arkenau HT(2015)PD-1/PD-L1 inhibitors Curr Opin Pharmacol 23 32-38

[3] Infante JR(2015)Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer Sci Rep 5 13110-988

[4] Sunshine J(2016)Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer J Thorac Oncol 11 976-54

[5] Taube JM(2015)Differential activity of Nivolumab, Pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers PLoS One 10 e0130142-331

[6] He J(2016)Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer JAMA Oncology 2 46-975

[7] Hu Y(2016)Programmed death ligand 1 immunohistochemistry: friend or foe? Arch Pathol Lab Med 140 326-1421

[8] Hu M(2016)PD-L1 expression in lung cancer J Thorac Oncol 11 964-222

[9] Li B(2017)PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability Mod Pathol 30 1411-567

[10] Shukuya T(2017)PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project J Thorac Oncol 12 208-361